아데노바이러스 유전자치료벡터의 생식독성 연구 = Potential Reproductive Toxicity Study of p53 Expressing Adenoviral Vector in Mice

국문 초록 (Abstract)

유전자치료W터의 주입시 생식세포를 통한 다음 세대로의 전달 가능성은 안전성 측면에서 관심을 중대시키고 있다. 특히 전립선암이나 난소암의 치료시 바이러스를 생식기관에 인접한 부위에 주입하여야 하므로 그 가능성이 높다. 따라서 본 연구에서는 유전자치료에 많이 이용되는 아데노바이러스를 매개로하여 tumor suppressor 유전자인 p53을 발현하는 아데노바이러스 벡터를 제조하여 이를 투여시 생식장기를 포함한 주요장기조직에의 분포와 germ cell을 통한 차세대로의 전달 가능성 등의 생식독성을 조사하였다. In vivo biodistribution study를 위하여 $Ad-CMV-{\beta}-gal$흑은 Ad-CMV-p53를 마우스 암 수의 복강에 주사한 후 생식장기를 포함한 주요 장기에서 아데노바이러스 유래 DNA검출 및 RNA발현 여부를PCR과 RT-PCR로 각각 확인하였다. 그 결과 간 및 비장과 같은 일반 장기에서도 주입한 외부유전자의 DNA가 검출되거나RNA가 발현되었을 뿐만 아니라, 정낭, 전립선, 부고환, 난소 및 자궁 등의 생식장기에서도 주입한 외부유전자가 검출되거나 발현되는 것으로 나타났다. Real-time PCR을 이용하여 각 장기에서의 투여된 아데노바이러스 벡터는 시간 의존적으로 감소되는 것을 정량하였다. Ad-CMV-p53를 암 수 마우스의 난소와 고환에 각각 직접 주사하여 교배시킨 후 그 후세대의 DNA를 분리하여 주입한 아데노바이러스 유래의 DNA를 검색한 결과, 어떠한 차세대에서도 주입한 아데노바이러스 유래의 DNA가 검출되지 않았다. 한편 생식장기에서의 PCR및 RT-PCR signal유래 vector의 위치를 확인하기 위해 매우 감도가 높은 in-situ PCR로 조사한 결과 고환의 경우 간질조직으로의 전달은 일어나나 정세관 내에는 아데노바이러스 벡터가 전달되지 않으며, 난소에서도 아데노바이러스벡터는 난포내의 난자에 전달되지 않고 기질조직에 존재하는 것으로 확인되었다. 결론적으로 복제 능력 이 결여된 아데노바이러스를 매개로 한 유전자치료제는 생식 장기에서 검출되더라도 다음 세대로 전달될 가능성은 대단히 낮음을 제시한다.

다국어 초록 (Multilingual Abstract)

The possibility of inadvertent introduction of therapeutic gene expressing viral vectors has raised safety concerns about germ-line infection. Particularly, for indications such as prostate cancer and ovarian cancer, the proximity of the point of viral administration to organs of the reproductive system raises concerns regarding inadvertent germ-line transmission of genes carried by the virus vector. To evaluate the safety of in vivo adenovirus mediated gene transfer, we explored the biodistribution, persistance and potential germ-line transmission of p53-expressing adenovirus (Ad-CMV-p53). Both male and female Balb/c mice were injected with $1{\times}10^9$ PFU of Ad-CMV-p53. The PCR analysis showed that there were detectable vector sequences in liver, kidney, spleen, seminal vesicle, epididymis, prostate, ovary, and uterus. The RT-PCR analysis for detecting inserted gene, p53 showed that Ad-CMV-p53 viral RNA were present in spleen, prostate and ovary. Direct injected male and female mice of adenovirus vector into testis and ovary were mated and their of offspring were evaluated for germ-line transmission of the adenoviral vector. The PCR and RT-PCR analysis showed no evidence of germline transmission, although vector sequences were detected in DNA extracted from gonadal tissues. Real-time PCR result confirmed a significant decrease of adenovirus in gonad tissues 1 week after injection. We have also analysed the cell specific localization of viral DNA in gonad tissues by using in-situ PCR. Positive signals were detected in interstitial tissue but not in seminiferous tubule in sperm. In the case of ovary, adenovirus signal were localized to the stromal tissue, but no follicular signals were observed. Together, these data provide strong evidence that the risk of the Inadvertent germ-line transmission of vector sequences following intraperitoneal or direct injection into genito-urinary system of adenovirus is extremely low.

참고문헌 (Reference)

1 "Virus treatment questioned after gene therapy death" 401 : 517-518, 1999

2 "Transgenesis by adenovirus-mediated gene transfer into mouse zona free eggs" 14 : 982-985, 1996

3 "Success and setback: Another adverse event" 6 : 565-566, 2002

4 "Recombinant DNA advisory committee" 2002

5 "Preclinical safety evaluation of human gene therapy products" 47 : 9-15, 1999

6 "Potential risk of inadvertent germ line gene transmission" 10 : 1593-1595, 1999

7 "Local inflammatory response and vector spread after direct intraprostactic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice" 5 : 74-82, 1998

8 "Lack of germline transmission of vectorsequences following systemic administration of recombinant AAV 2 vector in males" 4 : 586-591, 2001

9 "Germline gene therapy Yes or No" 4 : 1-, 2001

10 "Germline ateration by gene therapy Assessing and reducing the risks" 468-470, 1998.11

11 "Gene therapy and the germline" 5 : 245-, 1999

12 "Gene therapy and the germ line" 6 : 2-4, 2002

13 "Evaluation of the biodistribution toxicity and potential of germ line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse" 1 : 263-274, 2000

14 "Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse" 9 : 2135-2142, 1998

15 "Effects of adenovirus mediated gene transfer to mouse testis in vivo on spermatogenesis and next generation" 170 : 2109-2114, 2003

16 "Direct exposure of mouse spermatogenic cells to high doses of adenovirus gene therapy vector does not result in germ cell transduction" 11 : 1705-1712, 2000

17 "Direct exposure of mouse ovaries and oocytes to high doses of an adenovirus gene therapy vector fails to lead to germ cell transduction" 3 : 557-564, 2001

18 "Biodistribution of adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to mouse" 6 : 367-372, 1999

19 "Assessment of adenoviral vector safety and toxicity" 13 : 3-13, 2002

20 "Adenovirus mediated gene transfer to rat testis in vivo" 56 : 495-500, 1997